芪珍胶囊辅助治疗对乳腺癌T淋巴细胞亚群肿瘤标志物的影响及预后分析

doi:10.3969/j.issn.1006-6233.2023.11.032

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1283 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探究芪珍胶囊辅助治疗对乳腺癌T淋巴细胞亚群、肿瘤标志物及预后的影响。方法: 选2019年1月至2021年1月我院收入并治疗的乳腺癌患者80例为研究对象,依据随机数字表采用简单随机分组方法将其分为对照组、观察组,每组40例,两组患者均接受EC化疗干预方案(环磷酰胺+阿霉素+氟尿嘧啶),观察组在此基础上联合芪珍胶囊口服治疗,两组患者均连续治疗6周。比较两组患者血常规情况、T淋巴细胞亚群(CD3⁺、CD4⁺、CD8⁺)、肿瘤标志物指标[癌胚抗原(CEA)、糖类抗原153(CA153)、癌抗原125(CA125)]水平,截至随访2023年2月28日,分析两组患者中位无病生存期差异。结果: 治疗前,两组患者红细胞、白细胞、血小板比较无显著差异(P>0.05)。治疗后,观察组白细胞、血小板治疗前后差值大于对照组(P<0.05)。治疗前,两组患者CD3⁺、CD4⁺、CD8⁺比较无显著差异(P>0.05)。治疗后,观察组CD3⁺、CD4⁺治疗前后差值大于对照组(P<0.05)。治疗前,两组患者CEA、CA153、CA125比较无显著差异(P>0.05)。治疗后,两组CEA、CA153、CA125均降低,且观察组CEA、CA153、CA125治疗前后差值大于对照组(P<0.05)。截至随访2023年2月28日,观察组病情复发转移4例,对照组病情复发转移11例,与对照组相比,观察组无病生存期更高,生存优势更明显(χ²=7.195,P=0.007)。两组患者治疗不良反应发生率比较无显著差异(P>0.05)。结论: 芪珍胶囊辅助治疗可改善乳腺癌患者T淋巴细胞亚群、肿瘤标志物及术后生存情况,且用药安全性有一定保障。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：乳腺癌, 芪珍胶囊, T淋巴细胞亚群, 肿瘤标志物, 预后, EC化疗

Abstract：Objective: To explore the effect of Qizhen capsule on T lymphocyte subsets,tumor markers and prognosis of breast cancer. Methods: Eighty patients with breast cancer who received treatment at our hospital from January 2019 to January 2021 were selected for this study.They were randomly divided into a control group and an observation group,with 40 patients in each group.Both groups received the EC chemotherapy intervention (cyclophosphamide+doxorubicin+fluorouracil).Additionally,the observation group received Qizhen capsule as oral treatment.Both groups were treated continuously for 6 weeks.The study compared the blood routine status,T lymphocyte subpopulations (CD3⁺,CD4⁺,CD8⁺),and tumor marker indicators (carcinoembryonic antigen (CEA),carbohydrate antigen 153 (CA153),and cancer antigen 125 (CA125) levels between the two groups.As of the follow-up on February 28,2023,the study analyzed the difference in median survival time between the two groups. Results: Before treatment,there were no significant differences in red blood cells,white blood cells,and platelets between the two groups (P>0.05).After treatment,the difference in white blood cell and platelet counts before and after treatment in the observation group was greater than in the control group (P<0.05).Before treatment,there were no significant differences in CD3⁺,CD4⁺,and CD8⁺ between the two groups (P>0.05).After treatment,the difference in CD3⁺ and CD4⁺ before and after treatment in the observation group was greater than in the control group (P<0.05).Before treatment,there were no significant differences in CEA,CA153,and CA125 between the two groups (P>0.05).After treatment,CEA,CA153,and CA125 were decreased in both groups,with the difference in CEA,CA153,and CA125 before and after treatment in the observation group being greater than in the control group (P<0.05).As of February 28,2023,4 patients in the observation group experienced disease recurrence and metastasis,while 11 patients in the control group experienced recurrence and metastasis.Compared with the control group,the observation group had a higher disease-free survival rate,and the survival advantage was more pronounced (χ²=7.195,P=0.007).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Adjuvant treatment with Qizhen capsule can improve the T lymphocyte subsets,tumor markers,and postoperative survival of breast cancer patients,and the treatment is safe.

Key words： Breast cancer Qizhen capsules T lymphocyte subpopulations Tumor markers Prognosis EC chemotherapy

基金资助:河南省中医药科学研究专项课题,(编号:2022JDZX13)

通讯作者: 刘侠

引用本文:

徐梦姗, 庞欣欣, 刘侠, 岳亚丽, 张昭, 陈安玥, 毛杨. 芪珍胶囊辅助治疗对乳腺癌T淋巴细胞亚群肿瘤标志物的影响及预后分析[J]. 河北医学, 2023, 29(11): 1922-1926.
XU Mengshan, et al. Influence of Qizhen Capsule Adjuvant Therapy on T Lymphocyte Subsets Tumor Markers and Prognosis of Breast Cancer. HeBei Med, 2023, 29(11): 1922-1926.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2023.11.032 或 http://www.hbyxzzs.cn/CN/Y2023/V29/I11/1922